Actively Recruiting
Evaluating the Safety and Activity of GDC-7035 Alone and with Other Therapies in Advanced Solid Tumors with KRAS G12D Mutation
Led by Genentech, Inc. · Updated on 2026-10-23
410
Participants Needed
49
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, pharmacokinetics, and early activity of GDC-7035, both alone and combined with other anti-cancer therapies, in adults with advanced or metastatic solid tumors that have the KRAS G12D mutation. This first-in-human Phase III study is open-label and conducted at multiple centers, focusing on patients with this specific genetic tumor marker. Participants receive GDC-7035 in two study arms one with GDC-7035 alone and the other with GDC-7035 combined with other anti-cancer treatments. The study involves dose escalation and expansion phases with protocol-defined dosing to determine safe and effective dose levels. During the trial, participants are closely monitored for side effects, dose-limiting toxicities, and blood levels of the drug at specified times. Researchers measure response rates, duration of response, and progression-free survival over a period of up to four years. The study involves regular evaluations to assess safety and drug activity throughout the treatment period.
CONDITIONS
Brief Title
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Research Team
R
Reference Study ID Number: GO45416 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here